Clinical advances on amphiregulin and lung cancer
10.3760/cma.j.issn.1001-4497.2017.02.016
- VernacularTitle:双调蛋白与肺癌的临床研究进展
- Author:
Yuan XU
;
Kaidi LI
;
Chao GUO
;
Zhongxing BING
;
Naixin LIANG
;
Hui PAN
;
Shanqing LI
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2017;33(2):115-118
- CountryChina
- Language:Chinese
-
Abstract:
Amphiregulin is the ligand of epidermal growth factor receptor.It's widely expressed in many tissues and is involved in the oncogenesis,progression and metastasis of tumors.In the clinical study of lung caner,amphiregulin is a prognostic marker for NSCLC patients.Furthermore,amphiregulin is closely associated with the sensitivity and resistance of EGFRTKI treatment.Medicine target on amphiregulin can inhibit the activity of tumors.
